title: Methods and benefits of administration monitoring. Results obtained with flunisolid MDI in 3,742 patients with chronic obstructive airway diseases.
authors: Boehringer Ingelheim KG, Department of Medicine, Ingelheim, Germany.
authors: M E
authors: ME
authors: Köhler
authors: M
authors: M
authors: Kemmer
authors: K
authors: K
authors: Wolf
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D009330:Nebulizers and Vaporizers; D011358:Product Surveillance, Postmarketing; D012306:Risk
chemical_list: D000893:Anti-Inflammatory Agents; D005446:Fluocinolone Acetonide; C007734:flunisolide